{"id":3647,"date":"2020-12-10T17:02:38","date_gmt":"2020-12-10T22:02:38","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/"},"modified":"2026-09-24T00:08:36","modified_gmt":"2026-09-24T04:08:36","slug":"gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/","title":{"rendered":"GenSight Biologics annonce la conversion partielle des obligations convertibles et l’exercice de l’int\u00e9gralit\u00e9 des bons de souscription d’actions par Kreos Capital"},"content":{"rendered":"\nParis, France, le 10 d\u00e9cembre 2020, 18h00 CET<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME) (la \u00ab Soci\u00e9t\u00e9 <\/strong>\u00bb ou \u00ab GenSight <\/strong>\u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd’hui avoir re\u00e7u, dans le cadre de son emprunt obligataire conclu avec Kreos Capital VI (Expert Fund) LP (\u00ab\u00a0Kreos \u00a0<\/strong>\u00bb), la notification par Kreos de (i) la conversion de 50% des obligations convertibles des tranches A et B (au prix de 2,245 \u20ac par action), (ii) la conversion de 50% des obligations convertibles additionnelles de la tranche B (au prix de 2,574 \u20ac par action) et (iii) l’exercice de l’int\u00e9gralit\u00e9 des bons de souscription d’actions des tranches A et B (au prix de 2,245 \u20ac par action) repr\u00e9sentant une \u00e9mission totale de 1.182.953 actions ordinaires nouvelles.\n\nLe nombre total d’actions de la Soci\u00e9t\u00e9 pouvant \u00eatre \u00e9mises, dans le cadre de l’emprunt obligataire, par conversion des 50% restants (i) des obligations convertibles des tranches A et B (au prix de 2,245 \u20ac par action) et (ii) des obligations convertibles additionnelles de la tranche B (au prix de 2,574 \u20ac par action) est de 726.426 actions.\n\nLes actions nouvelles ont \u00e9t\u00e9 admises aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris le 10 d\u00e9cembre 2020.\n\n \n

\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il. D\u00e9velopp\u00e9 dans le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), le principal produit candidat de GenSight Biologics, LUMEVOQ\u00ae<\/sup> (GS010 ; lenadogene nolparvovec), est actuellement en cours d’examen pour enregistrement en Europe, et en phase III pr\u00e9alablement au d\u00e9p\u00f4t de la demande d\u2019autorisation de mise sur le march\u00e9 aux Etats-Unis (Biologics License Application<\/em> [BLA]).\n","protected":false},"excerpt":{"rendered":"

Paris, France, le 10 d\u00e9cembre 2020, 18h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab GenSight \u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd’hui avoir […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76,80],"post-year":[],"class_list":["post-3647","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"\nGenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'int\u00e9gralit\u00e9 des bons de souscription d'actions par Kreos Capital - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'int\u00e9gralit\u00e9 des bons de souscription d'actions par Kreos Capital - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 10 d\u00e9cembre 2020, 18h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab GenSight \u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd’hui avoir […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T22:02:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:08:36+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics annonce la conversion partielle des obligations convertibles et l’exercice de l’int\u00e9gralit\u00e9 des bons de souscription d’actions par Kreos Capital\",\"datePublished\":\"2020-12-10T22:02:38+00:00\",\"dateModified\":\"2026-09-24T04:08:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/\"},\"wordCount\":449,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/\",\"name\":\"GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'int\u00e9gralit\u00e9 des bons de souscription d'actions par Kreos Capital - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-12-10T22:02:38+00:00\",\"dateModified\":\"2026-09-24T04:08:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/12\\\/10\\\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce la conversion partielle des obligations convertibles et l’exercice de l’int\u00e9gralit\u00e9 des bons de souscription d’actions par Kreos Capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'int\u00e9gralit\u00e9 des bons de souscription d'actions par Kreos Capital - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'int\u00e9gralit\u00e9 des bons de souscription d'actions par Kreos Capital - GenSight Biologics","og_description":"Paris, France, le 10 d\u00e9cembre 2020, 18h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab GenSight \u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd’hui avoir […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/","og_site_name":"GenSight Biologics","article_published_time":"2020-12-10T22:02:38+00:00","article_modified_time":"2026-09-24T04:08:36+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics annonce la conversion partielle des obligations convertibles et l’exercice de l’int\u00e9gralit\u00e9 des bons de souscription d’actions par Kreos Capital","datePublished":"2020-12-10T22:02:38+00:00","dateModified":"2026-09-24T04:08:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/"},"wordCount":449,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/","name":"GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'int\u00e9gralit\u00e9 des bons de souscription d'actions par Kreos Capital - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2020-12-10T22:02:38+00:00","dateModified":"2026-09-24T04:08:36+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/12\/10\/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce la conversion partielle des obligations convertibles et l’exercice de l’int\u00e9gralit\u00e9 des bons de souscription d’actions par Kreos Capital"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3647"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3647\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3647"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3647"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3647"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3647"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}